UK MPs wants pharma in AIDS patent pool, while GSK makes new moves
This article was originally published in Scrip
Executive Summary
The prices of newer second-line antiretroviral treatments (ARTs) need to be urgently reduced to improve access to developing countries, says a new report by a group of UK members of Parliament. The report, The Treatment Timebomb, states that by 2030 more than 50 million people will need ARTs worldwide, compared with just nine million today.
You may also be interested in...
US FDA head Hamburg declares no one can inspect world on its own
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
FDA's Hamburg declares no one can "inspect world on its own" for poor quality medicines
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Pharma and MSF agree on competition for cheap vaccines, but differ on pricing
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.